Sodium–glucose cotransporter-2 (SGLT2) inhibitors have been shown to reduce the development, progression, and mortality of heart failure in patients with reduced EF regardless of patients’ diabetes status but their clinical benefits in patients with heart failure and preserved ejection fraction are less well-established. The gene discussed is SLC5A2; the disease is heart failure.